Display options
Cite
Kontis D, Boulougouris V, Papakosta VM, et al. Dopaminergic and serotonergic modulation of persistent behaviour in the reinforced spatial alternation model of obsessive-compulsive disorder. Psychopharmacology (Berl). 2008;200(4):597-610doi: 10.1007/s00213-008-1241-5.
Kontis, D., Boulougouris, V., Papakosta, V. M., Kalogerakou, S., Papadopoulos, S., Poulopoulou, C., Papadimitriou, G. N., & Tsaltas, E. (2008). Dopaminergic and serotonergic modulation of persistent behaviour in the reinforced spatial alternation model of obsessive-compulsive disorder. Psychopharmacology, 200(4), 597-610. https://doi.org/10.1007/s00213-008-1241-5
Kontis, Dimitris, et al. "Dopaminergic and serotonergic modulation of persistent behaviour in the reinforced spatial alternation model of obsessive-compulsive disorder." Psychopharmacology vol. 200,4 (2008): 597-610. doi: https://doi.org/10.1007/s00213-008-1241-5
Kontis D, Boulougouris V, Papakosta VM, Kalogerakou S, Papadopoulos S, Poulopoulou C, Papadimitriou GN, Tsaltas E. Dopaminergic and serotonergic modulation of persistent behaviour in the reinforced spatial alternation model of obsessive-compulsive disorder. Psychopharmacology (Berl). 2008 Nov;200(4):597-610. doi: 10.1007/s00213-008-1241-5. Epub 2008 Jul 14. PMID: 18622751.
Copy Download .nbib Format: NLM
Share it on

Psychopharmacology (Berl). 2008 Nov;200(4):597-610. doi: 10.1007/s00213-008-1241-5. Epub 2008 Jul 14.

Dopaminergic and serotonergic modulation of persistent behaviour in the reinforced spatial alternation model of obsessive-compulsive disorder.

Psychopharmacology

Dimitris Kontis, Vasileios Boulougouris, Vasiliki Maria Papakosta, Stamatina Kalogerakou, Socrates Papadopoulos, Cornelia Poulopoulou, George N Papadimitriou, Eleftheria Tsaltas

Affiliations

  1. Experimental Psychology Laboratory, Department of Psychiatry, Eginition Hospital, Athens University Medical School, 74, Vas. Sofias Ave., 115 28 Athens, Greece.

PMID: 18622751 DOI: 10.1007/s00213-008-1241-5

Abstract

RATIONALE: We have proposed rewarded T-maze alternation as a model of obsessive-compulsive disorder (OCD): the serotonin agonist m-chlorophenylpiperazine (mCPP) increments persistence therein, while chronic pretreatment with selective serotonin reuptake inhibitor (SSRI fluoxetine) but not benzodiazepine or desipramine abolishes mCPP effects. However, we noted that acute SSRI administration also causes transient persistence increase, counteracted by mCPP pretreatment.

OBJECTIVES: This study (a) further explores the cross-tolerance between fluoxetine and mCPP and (b) extends the model by investigating its sensitivity to dopaminergic manipulations (D2, 3 agonism--quinpirole).

MATERIALS AND METHODS: In both experiments, baseline and drug testing were carried out under daily T-maze alternation training. Exp. 1: Matched group (n = 8) pairs of rats received one of the following 20-day pretreatments (daily intraperitoneal administration): (1) saline, (2) low-dose fluoxetine (2.5 mg/kg), (3) low-dose mCPP (0.5 mg/kg) or (4) combined fluoxetine + mCPP. One group per pretreatment then received a 4-day challenge with high-dose fluoxetine (10 mg/kg), the other with high-dose mCPP (2.5 mg/kg). Exp. 2: One group (n = 12) of rats received 20-day treatment with saline, another with quinpirole (0.5 mg/kg).

RESULTS: Exp. 1: Saline and low-dose mCPP- or fluoxetine-pretreated animals showed significant persistence increases under both challenges, while combined low-dose fluoxetine + mCPP pretreatment afforded full protection from either challenge. Exp. 2: Quinpirole significantly increased directional persistence after 13 administration days.

CONCLUSIONS: These results establish the sensitivity of the rewarded alternation OCD model to D2, 3 receptor activation, thereby extending its profile of pharmacological isomorphism with OCD. Furthermore, they suggest a common mechanism of action of an SSRI and a serotonin agonist in the control of directional persistence.

References

  1. J Clin Psychiatry. 2004;65 Suppl 14:11-7 - PubMed
  2. Arch Gen Psychiatry. 1986 Dec;43(12):1180-2 - PubMed
  3. Behav Neurosci. 1998 Dec;112(6):1475-85 - PubMed
  4. Neuropsychopharmacology. 2005 Dec;30(12):2205-15 - PubMed
  5. Clin Neuropharmacol. 2001 Jul-Aug;24(4):191-207 - PubMed
  6. J Clin Psychopharmacol. 1992 Feb;12(1):11-8 - PubMed
  7. J Pharmacol Exp Ther. 1998 Aug;286(2):913-24 - PubMed
  8. Neuroscience. 1998 Apr;83(3):781-9 - PubMed
  9. J Neurosci. 1999 Jun 15;19(12):5044-53 - PubMed
  10. Behav Brain Res. 2006 Feb 15;167(1):49-56 - PubMed
  11. Biol Psychiatry. 2005 May 15;57(10):1176-85 - PubMed
  12. J Clin Psychiatry. 1994 Mar;55 Suppl:24-31 - PubMed
  13. Biol Psychiatry. 1991 Mar 1;29(5):418-26 - PubMed
  14. Br J Psychiatry Suppl. 1998;(35):26-37 - PubMed
  15. Arch Gen Psychiatry. 1988 Dec;45(12):1094-9 - PubMed
  16. Arch Gen Psychiatry. 2000 Jan;57(1):76-82 - PubMed
  17. Psychoneuroendocrinology. 2001 Feb;26(2):209-23 - PubMed
  18. J Clin Psychiatry. 1990 Aug;51 Suppl:36-43; discussion 55-8 - PubMed
  19. Brain Res. 1989 Jun 26;490(2):255-67 - PubMed
  20. Naunyn Schmiedebergs Arch Pharmacol. 1986 Aug;333(4):342-8 - PubMed
  21. BMC Neurosci. 2001;2:4 - PubMed
  22. Pharmacol Biochem Behav. 1994 Aug;48(4):921-8 - PubMed
  23. Biol Psychiatry. 1998 Sep 1;44(5):313-23 - PubMed
  24. Biol Psychiatry. 2004 May 15;55(10):1041-5 - PubMed
  25. Psychiatry Res. 1992 Apr;42(1):41-51 - PubMed
  26. Biol Psychiatry. 1999 Jan 15;45(2):164-74 - PubMed
  27. Biol Psychiatry. 2002 Jan 15;51(2):164-71 - PubMed
  28. J Neuropsychiatry Clin Neurosci. 1989 Winter;1(1):27-36 - PubMed
  29. J Neurosci. 2003 Sep 24;23(25):8771-80 - PubMed
  30. Br J Psychiatry Suppl. 1998;(35):13-20 - PubMed
  31. Arch Gen Psychiatry. 1992 Jul;49(7):517-21 - PubMed
  32. Neuropharmacology. 1999 Aug;38(8):1083-152 - PubMed
  33. CNS Spectr. 2005 Mar;10(3):191-202 - PubMed
  34. J Neurosci. 1998 Dec 1;18(23):10045-52 - PubMed
  35. Harv Rev Psychiatry. 2002 May-Jun;10(3):127-37 - PubMed
  36. Am J Med Genet. 1994 Sep 15;54(3):253-5 - PubMed
  37. Arch Gen Psychiatry. 1994 Apr;51(4):302-8 - PubMed
  38. J Clin Psychiatry. 1992 Apr;53 Suppl:17-28 - PubMed
  39. J Clin Psychiatry. 2002;63 Suppl 6:20-9 - PubMed
  40. Am J Psychiatry. 1995 Dec;152(12):1812-4 - PubMed
  41. Biol Psychiatry. 1997 Jan 15;41(2):226-9 - PubMed
  42. Arch Gen Psychiatry. 1992 Jan;49(1):21-8 - PubMed
  43. Arch Gen Psychiatry. 1988 Feb;45(2):177-85 - PubMed
  44. Biol Psychiatry. 1997 Nov 15;42(10):889-97 - PubMed
  45. Psychiatry Res. 1998 Jun 2;79(1):11-20 - PubMed
  46. Arch Gen Psychiatry. 1987 Nov;44(11):946-51 - PubMed
  47. Exp Neurol. 1972 Aug;36(2):362-77 - PubMed
  48. Biol Psychiatry. 1995 Aug 1;38(3):138-49 - PubMed
  49. Behav Brain Res. 2007 May 16;179(2):219-28 - PubMed
  50. Psychiatr Genet. 1998 Autumn;8(3):163-9 - PubMed
  51. Neuropsychopharmacology. 1995 Oct;13(2):117-27 - PubMed
  52. Psychiatry Res. 1991 Jan;36(1):1-17 - PubMed
  53. Biol Psychiatry. 1987 Jun;22(6):667-87 - PubMed
  54. Behav Brain Res. 2007 Feb 12;177(1):51-60 - PubMed
  55. Psychiatr Clin North Am. 2000 Sep;23(3):563-86 - PubMed
  56. Neuropsychopharmacology. 2003 Jan;28(1):77-85 - PubMed
  57. Behav Brain Res. 2007 Jun 18;180(2):241-5 - PubMed
  58. Biol Psychiatry. 1991 Aug 1;30(3):225-32 - PubMed
  59. J Affect Disord. 2004 Oct 15;82(2):167-74 - PubMed
  60. Arch Gen Psychiatry. 1990 Jun;47(6):577-85 - PubMed

Substances

MeSH terms

Publication Types